GlassScriptPhysician profile
Brittany B Deberry
NPI 1891722179
$1,600.71
in general payments reported to CMS, 2019-2025
27 companies · $600 in 2025
The $600 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2021: $37.62 · 2023: $218 · 2024: $620 · 2025: $600.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,438.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,438.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Molli Surgical (US) INC | $485.25 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $181.70 | 2023-2025 | Enhertu, Lynparza |
| Hologic INC | $124.99 | 2019 | |
| Merck Sharp & Dohme LLC | $90.47 | 2024-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Servier Pharmaceuticals LLC | $77.93 | 2024-2025 | |
| Genentech USA, INC. | $75.45 | 2024-2025 | Polivy, Lunsumio, Columvi |
| Takeda Pharmaceuticals U.S.A., INC. | $63.86 | 2025 | Iclusig, Alunbrig |
| Janssen Biotech, INC. | $52.94 | 2025 | Balversa, Akeega, Erleada |
| Incyte Corporation | $47.98 | 2025 | Monjuvi, Zynyz, Jakafi |
| Bayer Healthcare Pharmaceuticals INC. | $46.34 | 2024-2025 | |
| Lilly USA, LLC | $25.61 | 2025 | Jaypirca, Verzenio |
| Iovance Biotherapeutics, INC. | $25.35 | 2025 | Amtagvi |
| Novartis Pharmaceuticals Corporation | $23.57 | 2025 | |
| Sobi, INC | $23.37 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $22.27 | 2025 | Libtayo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $22.10 | 2023 | Rezlidhia, Tavalisse |
| Geron Corporation | $20.89 | 2025 | Rytelo |
| Stemline Therapeutics INC. | $20.52 | 2025 | Orserdu |
| Aveo Pharmaceuticals, INC. | $20.45 | 2025 | |
| Karyopharm Therapeutics INC. | $19.92 | 2024 | Xpovio |
| Genmab U.S., INC. | $19.44 | 2024 | Epkinly |
| Glaxosmithkline, LLC. | $19.24 | 2021 | |
| Alexion Pharmaceuticals, INC. | $19.22 | 2025 | Ultomiris |
| Daiichi Sankyo INC. | $19.06 | 2024 | Enhertu |
| Amgen INC. | $18.38 | 2021 | |
| Jazz Pharmaceuticals INC. | $17.29 | 2025 | |
| Azurity Pharmaceuticals, INC. | $17.12 | 2025 | Danziten |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittany Deberry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.